Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

COVID Collaborations: Two Ways To Define Success

Executive Summary

In the short term, public-private partnerships engaged in the coronavirus response will be judged on whether there are effective treatments for COVID-19. But the long-term impact may be as a test of whether collaborative models can work when the stakes are high.

You may also be interested in...



Trump’s ‘Warp Speed’ Initiative Could Fund 3 to 5 Large-Scale COVID Vaccine Trials

FDA’s Peter Marks and Janet Woodcock will be on the bridge for Operation Warp Speed; Moncef Slaoui says early clinical data on one vaccine candidate makes him confident that a few hundred million doses of a vaccine can be available by the end of the year.

NIH Partnership To Pick COVID-19 Therapeutics For Clinical Trials; Results Anticipated By Summer

NIH public-private partnership with FDA, CDC, BARDA and 16 biopharma companies to rank most promising therapeutics and vaccines to advance into clinical trials; candidates expected to be tested simultaneously under master protocol.

COVID-19 Partnerships Without Formal Contracts Pose Risks, From Potential Liability To IP Issues

Companies are racing to co-develop coronavirus treatments before finalizing deal teams. These team-ups raise questions about what happens after the pandemic subsides.

Topics

UsernamePublicRestriction

Register

ID1132298

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel